Darshan Patel, MD
Urology · San Diego, CANPI 1417342924
Payments from drug & device makers
Across 143 payments — averaging $78.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$5K
- Boston Scientific$3K
- Coloplast$2K
- Teleflex LLC$174
- Medtronic$162
- Endo USA, Inc.$147
- plus $482 from 9 others
What the payments were for
- Consulting fees$4,52541%
- Grants$1,47113%
- Travel & lodging$3583%
- Food & beverage$4,70642%
- Education$1031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 19 | $5,144 |
| Boston Scientific | 74 | $3,146 |
| Coloplast | 28 | $1,907 |
| Teleflex LLC | 2 | $174 |
| Medtronic | 2 | $162 |
| Endo USA, Inc. | 6 | $147 |
| Innovation Technologies Inc | 1 | $111 |
| Antares Pharma, Inc. | 3 | $91 |
| Tolmar, Inc. | 1 | $77 |
| EDAP Technomed Inc | 1 | $67 |
| Profound Medical Corp. | 1 | $42 |
| Baxter Healthcare | 1 | $37 |
| Olympus America Inc. | 2 | $28 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,163 in reported general payments places this provider in the 75th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 28 | $26,081 |
| MyrbetriqMirabegron | 25 | $20,347 |
| Testosterone | 55 | $3,205 |
| Testosterone Cypionate | 41 | $2,510 |
| Tamsulosin Hcl | 104 | $1,326 |
| Solifenacin Succinate | 17 | $906 |
| Celecoxib | 12 | $777 |
| Finasteride | 44 | $433 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 13 | $358 |
| Tadalafil | 11 | $231 |
| Cephalexin | 13 | $133 |
| Sildenafil Citrate | 30 | $48 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $34 |
Paid to pharmacies, not to this prescriber.
Other urology in San Diego
- Ithaar DerweeshSan Diego$1.6M
- Amirali SalmasiSan Diego$1.3M
- Elward CrawfordSan Diego$866K
- Roger SurSan Diego$741K
- William MoseleySan Diego$379K
- Irwin GoldsteinSan Diego$361K
- Seth BechisSan Diego$311K
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.